Pharma Journalist 8947 posts 0 comments

Horizon Therapeutics plc announced that the U.S. Food and Drug Administration (FDA) has approved TEPEZZATM (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED). TEPEZZA is…
Read More...

GlaxoSmithKline plc announced the US Food and Drug Administration (FDA) granted a priority review for the company’s Biologics License Application (BLA) seeking approval of belantamab…
Read More...

Today, the U.S. Food and Drug Administration (FDA) approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a rare condition where the muscles and…
Read More...

Armas Pharmaceuticals Inc. (Armas), has begun the new year with launches of four generic injectables: Caffeine Citrate, Docetaxel, Gemcitabine and Verapamil HCI. These products are now…
Read More...

SMi Reports: SMi’s Pharmaceutical Microbiology Conference series will feature an exciting agenda and expert speaker line-up. SMi Group are pleased to host the 3rd Annual…
Read More...

AstraZeneca’s Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted Orphan Drug Designation (ODD) in the US for the treatment…
Read More...

Novartis announced the European Commission (EC) has approved Mayzent (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active…
Read More...

FDF China, collocated with CPhI China, will be held from June 22-24, 2020 at Shanghai New International Expo Centre (SNIEC). More and more formulation enterprises need to implement…
Read More...

As the pharmaceutical market demands in China continue to grow, China’s pharmaceutical policies become gradually clear, which provides broad space for the development of pharmaceutical…
Read More...

Global procurement management of pharmaceutical packaging materials has become a hot issue that all pharmaceutical enterprises are facing…
Read More...